Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim in Alcoholic Hepatitis
NCT02776059Phase 2Completed
- Start
- Jan 2017
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegfilgrastim in alcoholic hepatitis (AH) (2 arms). Primary endpoints: Adverse events, especially infection and renal failure at Day 90, Change in Model for End-stage Liver Disease Score at Day 29 and 2 more. Started Jan 2017; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT02776059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02776059.